HUE035726T2 - Sejtterápiás formálási eljárás és készítmény - Google Patents
Sejtterápiás formálási eljárás és készítmény Download PDFInfo
- Publication number
- HUE035726T2 HUE035726T2 HUE05724065A HUE05724065A HUE035726T2 HU E035726 T2 HUE035726 T2 HU E035726T2 HU E05724065 A HUE05724065 A HU E05724065A HU E05724065 A HUE05724065 A HU E05724065A HU E035726 T2 HUE035726 T2 HU E035726T2
- Authority
- HU
- Hungary
- Prior art keywords
- cells
- ára ára
- infusion
- agents
- container
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 39
- 238000009472 formulation Methods 0.000 title description 11
- 238000002659 cell therapy Methods 0.000 title description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 105
- 238000001802 infusion Methods 0.000 claims abstract description 52
- 239000000463 material Substances 0.000 claims abstract description 49
- 210000004027 cell Anatomy 0.000 claims abstract description 40
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 28
- 239000004005 microsphere Substances 0.000 claims abstract description 17
- 239000002077 nanosphere Substances 0.000 claims abstract description 16
- 238000004113 cell culture Methods 0.000 claims abstract description 11
- 230000004913 activation Effects 0.000 claims description 19
- 230000003993 interaction Effects 0.000 claims description 5
- 240000004770 Eucalyptus longicornis Species 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000004132 cross linking Methods 0.000 abstract description 18
- 238000004806 packaging method and process Methods 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 9
- 230000003213 activating effect Effects 0.000 abstract description 8
- 241000283707 Capra Species 0.000 abstract description 5
- 241001494479 Pecora Species 0.000 abstract description 3
- 239000011248 coating agent Substances 0.000 abstract description 2
- 238000000576 coating method Methods 0.000 abstract description 2
- 239000012634 fragment Substances 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 210000004698 lymphocyte Anatomy 0.000 description 26
- 230000010412 perfusion Effects 0.000 description 10
- 238000002156 mixing Methods 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- -1 poly(lactic acid) Polymers 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000008102 immune modulation Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000009520 phase I clinical trial Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229920003232 aliphatic polyester Polymers 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 101150022035 exog gene Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2531/00—Microcarriers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
- C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Claims (3)
- Smttmapms torntabs? eliams e\ boonmens Szabadalmi: igénypontok1, Készítmény, mely kezeléshez hatékony mennyiségű sejtet tartalmaz, melyek egy része T» sejt, ahol a T-sejtek sejttant C'vetS'l kenitek kot>ereste, és így eikűlönítéttak a tenyészetben leve stímulusokték és a kimert Piátok mfoztc eehata formáltak, mely eljárás során (1) a 'T-•sejteket egy vagy több szerrel er.ntkwíetink, mehek a T-sejtek legalább egy részén levő sejt-felületi gyökökhöz ligalódnak ¢,-1 az eg> \ agy több szert az egy vagy több szerrel térhálósod-ni képes anyaggal bevont bteiogkm.m lebontható nanoszférákkal vagy tnlkroszférákkal térhá-losütúk, 13} a T-Séjteket, az agy vagy több szart és a bevont. biológiailag lebontható nanoszíérákat vagy míkroszférákat egy inleziós közegben szuszpedáljük, és (4) egy megfelelő tartályba töltjük, ahol a T-sejtek a közegben aktivált állapotban vannak.
- 2. Az 1. igénypont szerinti készítmény, ahol a közeg paremerábs infúzióm alkalmas. X Az 1« vagy 2. igénypont szerinti készítmény, ahol a tartály ősszehaítható. 4< ÁZ. 1-3. igénypontok bármelyike szerinti készítmény, ahol a tartálynak egy fecskendő része van.. §. Eljárás kezelésre hatásos mennyiségű sejtek előállítására, melyek egy része T*sejt, ahol a T-sejíek sejttenyészetböl kerültek kinyerésre, és Így elkülönítettek a tenyészetben levő stitnulusoktól, mely eljárás során az Izolált T-sej leket infúzióvá formáljuk .az alábbi ntódszeo ;e! (Pa kutsa· I kkc m \ va <, pk snchek xahoak a I s|tt\lM eo nki \U tHÍn\!uUex'lbvt".Al· rso^a t m \>ek ea n, ,?'> i <. «. ? \e ,\e ? 1 sejtek felületi gyökeihez kapesoM szerrel térhálösödni képes anyaggal bevont biológiailag •eborrtbató .oarmxtórákkal \aeo ηηΚη>»Ά',Χ·\Χ vAOMUk fo) a;eXi xeuek «.s a hm ont biológiailag lebontható szférák keverékét egy infúziós közegben szuszpedáljuk, ahol a T-\rtte\ oktunk alkmotö.o! xmrak m X'· akekeket eg\ alhámax entabba <\om.,s oút k t \ ' s c \ s ' n \ m k\floú' ee\ u > μ n , s zsák, ?. Az 5. igénypont szerinti eljárás, ahol a tartály összehajtható. b \ ' tgC't'.pettí \/etme ehat e> $hel ? fait,J> flextb.bs aroualM ti o \.\T-k>v t tt eket t ' egy kilépő ».sö\et mrtalmaz. « 1 Ijnras kezelésre hatásos mennyiségű sejtek előállítására,, melyek egy része T-sejk ahol a 1 sv}te\ sejtiemesze;ból Irnttíltek ktmete'oe, és így eikulóoítettek a tenses/etlvn lev> stnnulnsekto' mels ehe es s, te? ùrsc. I M‘>.eks rlu oosa lerr J as , alab m noos vt rel: il) kinyert T-sejtek egy populációját egy első anyaggal és egy vagy több második anyaggal bevont biológiailag lebontható atmoszférákkal vagy mikroszférákkal keverjük, ahol az első anyaga második anyagokkal térhálósodik. és a második anyagok reagálni képesek a 1-sejtek felületén levő gyökökkel és ahol a második anyagok és a T-sejtek kölcsönhatasa a I -sejtek aktiválódását eredményezi; te) a T-sejtek ós a biológiailag lebontható szférák keverékét egy mín/no kó/i.gben s. m/pesvUlmk ah-fl a 1 -sejtek akto uh allupotbuu \annak, és te; a keveréket, egy alkalmas tartályba csomagoljuk. Ifl \ o tgem.poot szirti el más, ehol a aitah cos leeskemm \ag\ eeo 1\ upusu adu/1 's zsák.
- 11. Λ igenypmu szentül ehatas. ahol a untai) összehajtható 12. Ä 11. igénypont szerinti eljárás,, ahol a tartály flexibilis anyagból álló szemközti falakat és e< V Oiejxs estnU urta'"s,e 13. A. 9. igénypont szerinti eljárás, ahol a csomagolt keverék T»sejt koncentrációja legalább ,1X 1Ö! sejt per ml infúziós közeg.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54903204P | 2004-03-01 | 2004-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE035726T2 true HUE035726T2 (hu) | 2018-05-28 |
Family
ID=34919427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE05724065A HUE035726T2 (hu) | 2004-03-01 | 2005-03-01 | Sejtterápiás formálási eljárás és készítmény |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP1749090B1 (hu) |
| JP (3) | JP5144250B2 (hu) |
| CA (1) | CA2530514C (hu) |
| DK (1) | DK1749090T3 (hu) |
| ES (1) | ES2635868T3 (hu) |
| HU (1) | HUE035726T2 (hu) |
| IL (3) | IL173405A (hu) |
| PL (1) | PL1749090T3 (hu) |
| PT (1) | PT1749090T (hu) |
| WO (1) | WO2005084276A2 (hu) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110142887A1 (en) * | 2009-12-15 | 2011-06-16 | Immunovative Therapies Ltd. | Methods and compositions for liquidation of tumors |
| US7592431B2 (en) | 2004-02-26 | 2009-09-22 | Immunovative Therapies, Ltd. | Biodegradable T-cell Activation device |
| EP2573166B1 (en) | 2004-02-26 | 2016-05-11 | Immunovative Therapies, Ltd. | Methods for preparing T-cells for cell therapy |
| AU2012250794B2 (en) | 2011-05-03 | 2015-11-05 | Immunovative Therapies, Ltd. | Methods for handling biological drugs containing living cells |
| SG10201901391RA (en) | 2011-05-03 | 2019-03-28 | Immunovative Therapies Ltd | Induction of il-12 using immunotherapy |
| SG10201908048QA (en) | 2014-01-08 | 2019-10-30 | Immunovative Therapies Ltd | Treatment of Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766920A (en) | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
| WO1988000970A2 (en) | 1986-08-08 | 1988-02-11 | Regents Of The University Of Minnesota | Method of culturing leukocytes |
| US6534055B1 (en) * | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) * | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| CA2065658A1 (en) * | 1991-04-19 | 1992-10-20 | Tse-Wen Chang | Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators |
| AU5729294A (en) * | 1992-11-25 | 1994-06-22 | Tanox Biosystems, Inc. | Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules |
| EP0700430B1 (en) * | 1993-06-04 | 2005-04-20 | The United States of America as Represented by the Secretary of the Navy | Methods for selectively stimulating proliferation of t cells |
| AU7478394A (en) | 1993-08-06 | 1995-02-28 | Cytel Corporation | Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl |
| AU1333195A (en) * | 1994-06-03 | 1996-01-04 | Dana-Farber Cancer Institute | Methods for selectively stimulating proliferation of t cells |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6461867B1 (en) | 1995-03-08 | 2002-10-08 | The Scripps Research Institute | Synthetic antigen presenting matrix |
| AU738538B2 (en) | 1997-01-31 | 2001-09-20 | Hemosol Inc. | Method for the production of selected lymphocytes |
| US20030119185A1 (en) * | 2000-02-24 | 2003-06-26 | Xcyte Therapies, Inc. | Activation and expansion of cells |
| AU2002342299A1 (en) * | 2001-10-31 | 2003-05-12 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of | Generation of use of tc1 and tc2 cells |
| WO2003057171A2 (en) * | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
| US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| EP2573166B1 (en) * | 2004-02-26 | 2016-05-11 | Immunovative Therapies, Ltd. | Methods for preparing T-cells for cell therapy |
-
2005
- 2005-03-01 WO PCT/US2005/006446 patent/WO2005084276A2/en active Application Filing
- 2005-03-01 EP EP05724065.7A patent/EP1749090B1/en active Active
- 2005-03-01 EP EP17162282.2A patent/EP3202895A1/en not_active Withdrawn
- 2005-03-01 JP JP2007501882A patent/JP5144250B2/ja active Active
- 2005-03-01 HU HUE05724065A patent/HUE035726T2/hu unknown
- 2005-03-01 CA CA2530514A patent/CA2530514C/en active Active
- 2005-03-01 PT PT57240657T patent/PT1749090T/pt unknown
- 2005-03-01 PL PL05724065T patent/PL1749090T3/pl unknown
- 2005-03-01 ES ES05724065.7T patent/ES2635868T3/es active Active
- 2005-03-01 DK DK05724065.7T patent/DK1749090T3/en active
-
2006
- 2006-01-29 IL IL173405A patent/IL173405A/en active IP Right Grant
-
2010
- 2010-12-23 IL IL210244A patent/IL210244A0/en unknown
-
2011
- 2011-10-27 JP JP2011236442A patent/JP5649551B2/ja active Active
-
2012
- 2012-12-27 IL IL223938A patent/IL223938B/en active IP Right Grant
-
2014
- 2014-01-30 JP JP2014015195A patent/JP2014077018A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007526314A (ja) | 2007-09-13 |
| WO2005084276A2 (en) | 2005-09-15 |
| PT1749090T (pt) | 2017-08-28 |
| EP3202895A1 (en) | 2017-08-09 |
| EP1749090A4 (en) | 2009-04-29 |
| IL223938B (en) | 2020-01-30 |
| JP5649551B2 (ja) | 2015-01-07 |
| IL173405A0 (en) | 2006-06-11 |
| EP1749090A2 (en) | 2007-02-07 |
| JP2014077018A (ja) | 2014-05-01 |
| IL173405A (en) | 2011-02-28 |
| DK1749090T3 (en) | 2017-09-04 |
| ES2635868T3 (es) | 2017-10-05 |
| PL1749090T3 (pl) | 2017-12-29 |
| WO2005084276A3 (en) | 2007-05-10 |
| IL210244A0 (en) | 2011-03-31 |
| EP1749090B1 (en) | 2017-05-17 |
| JP5144250B2 (ja) | 2013-02-13 |
| JP2012021033A (ja) | 2012-02-02 |
| CA2530514C (en) | 2017-01-31 |
| CA2530514A1 (en) | 2005-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8778678B2 (en) | Composition of activated CD4 cells | |
| US7402431B2 (en) | T-cell therapy formulation | |
| JP6216793B2 (ja) | 可動性ナノマトリックスによるｔ細胞のポリクローナル刺激方法 | |
| US8105793B2 (en) | Process for in vivo treatment of specific biological targets in bodily fluids | |
| CN105431523A (zh) | 纳米级人工抗原呈递细胞 | |
| HUE035726T2 (hu) | Sejtterápiás formálási eljárás és készítmény | |
| ES2612918T3 (es) | Método para inducir la proliferación de células asesinas naturales por nanomatrices móviles | |
| CN109475620A (zh) | 抗原特异性t细胞的生产 | |
| WO1999029306A1 (en) | Devices for cloaking transplanted cells | |
| US10881692B2 (en) | Compositions for establishing mixed chimerism and methods of manufacture thereof | |
| Wang et al. | Cellular bioparticulates with therapeutics for cancer immunotherapy | |
| Davis et al. | The targeting of drugs using polymeric microspheres | |
| EP1571204B1 (de) | Leukozytenstimulations-Matrix | |
| Wee et al. | Cell surface modification by activated polyethylene glycol prevents allosensitization after islet transplantation | |
| Mashayekhi et al. | Biomaterial-enhanced treg cell immunotherapy: A promising approach for transplant medicine and autoimmune disease treatment | |
| Xing et al. | A specific immune tolerance toward offspring cells is to exist after the mother lymphocyte infusion | |
| AU2022378730A1 (en) | Beads for targeted signal delivery | |
| Gordon | The cytolytic response to P511 mastocytoma cell growth in mouse brain |